

2017-2018 POCC Lecture Series

September 28, 2017, 7:30 PM

Dr. Philip A. Harris
GlaxoSmithKline

Identification of a first-in-class RIP1 kinase inhibitor in phase 2a clinical trials for immuno-inflammatory diseases

Carolyn Hoff Lynch Lecture Hall
Chemistry Building, University of Pennsylvania

The Philadelphia Organic Chemist's Club

POCClub.org

Sponsored by PerkinElmer OneSource® Laboratory Services

Philip completed his B.S. in chemistry in 1985 at the University of Manchester UK, followed by a Ph.D. under Professor John Joule in heterocyclic chemistry in 1988. Philip then moved to the University of Florida for post-doc research with Professor Alan R. Katritzky, before then joining Burroughs Wellcome (later to become GlaxoWellcome and now GSK) in 1992 at Research Triangle Park in North Carolina. Philip was primarily part of a research group in RTP focused on kinase inhibitors for oncology which resulted in development of Votrient and Tafinlar, currently used for the treatment of kidney cancer and melanoma, respectively. On relocating to Collegeville in 2006, Philip switched therapeutic area focus to immuno-inflammation, where he is currently a Director in Medicinal Chemistry, focused on pattern recognition receptors and targeting inhibitors of the inflammasome and more recently RIP1 kinase.

Abstract: Receptor interaction protein 1 (RIP1) kinase activity has been shown to be critical driver of cell death and pro-inflammatory cytokine production downstream of multiple signaling pathways including TNFR1 and inhibitors of this kinase could potentially have a broad therapeutic benefit for multiple inflammatory diseases. We identified a novel and highly kinase selective RIP1 inhibitor series from a DNA-encoded library screen and this presentation will highlight the lead optimization and SAR of this series that led to identification of the development candidate GSK2982772 now under phase 2a clinical evaluation in psoriasis, rheumatoid arthritis and ulcerative colitis patients.